Short overview on the current treatment of chronic myeloid leukemia in chronic phase

about

Short overview on the current treatment of chronic myeloid leukemia in chronic phase

Item

http://www.wikidata.org/entity/Q37512201

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Short overview on the current treatment of chronic myeloid leukemia in chronic phase

@en

Short overview on the current treatment of chronic myeloid leukemia in chronic phase.

@nl

type

Item

label

Short overview on the current treatment of chronic myeloid leukemia in chronic phase

@en

Short overview on the current treatment of chronic myeloid leukemia in chronic phase.

@nl

prefLabel

Short overview on the current treatment of chronic myeloid leukemia in chronic phase

@en

Short overview on the current treatment of chronic myeloid leukemia in chronic phase.

@nl

P1476

Short overview on the current treatment of chronic myeloid leukemia in chronic phase

@en

P2093

Stefan Schmidt

http://www.w3.org/2001/XMLSchema#string

P2860

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.

The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs.

Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.

A review of the European LeukemiaNet recommendations for the management of CML.

P2888

s12254-016-0299-8

P304

157-162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12254-016-0299-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28058062

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

chronic myeloid leukemia

P932

5165029

http://www.w3.org/2001/XMLSchema#string